Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTampere University Hospital

About this trial

The goal of this one-arm clinical trial is to implement and study the oncological outcomes of nonoperative management of rectal cancer having complete clinical response to neoadjuvant therapy. The main questions to answer are

* if the oncological results of nonoperative management after Nordic practice in chemoradiotherapy indications differ from experiences elsewhere * what is the organ preservation rate * what is the local regrowth rate

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Histopathological verification of primary rectal adenocarcinoma

Complete clinical response at response assessment after neoadjuvant therapy

Informed consent to organ preservation study

Disqualifiers

Evidence of metastatic disease (fulfilling M-class criteria of TNM)

No neoadjuvant therapy

Inability to understand the information related to harms and benefits

Trial design

Design model

Single group

Treatments tested in this trial

  • Nonoperative surveillance

    Procedure/Surgery

    Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: Nonoperative managementExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Disease-free survival

Survival from complete clinical response to locoregional failure or distant metastases

Time frame
2 years

Secondary outcomes

1

Overall survival

Survival from complete clinical response to death or censoring of observation

Time frame
5 years
2

TME-free survival

Survival from complete clinical response to total mesorectal excision surgery

Time frame
5 years
3

ctDNA-free survival

Survival from complete clinical response to positive ctDNA result

Time frame
5 years
4

Post local regrowth disease-free survival

Survival from operated local regrowth to recurrence

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tampere University Hospital

Lead sponsor

Tampere University

Collaborator

Helsinki University Central Hospital

Collaborator

Turku University Hospital

Collaborator

Kuopio University Hospital

Collaborator

Oulu University Hospital

Collaborator

Jyväskylä Central Hospital

Collaborator

Seinajoki Central Hospital

Collaborator

Satakunta Central Hospital

Collaborator

North Karelia Central Hospital

Collaborator

Tartu University Hospital

Collaborator

East Tallinn Central Hospital

Collaborator

West Tallinn Central Hospital

Collaborator

North Estonia Medical Centre

Collaborator

Vaasa Central Hospital, Vaasa, Finland

Collaborator